9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial

9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy

European Journal of Cancer ◽

10.1016/s0959-8049(11)72331-0 ◽

2011 ◽

Vol 47 ◽

pp. S598

Author(s):

J. von Pawel ◽

R. Pirker ◽

J.R. Pereira ◽

M. Krzakowski ◽

K. Park ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Egfr Expression ◽

Epidermal Growth ◽

Patient Subgroups

Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Journal of Chinese Pharmaceutical Sciences ◽

10.5246/jcps.2021.03.021 ◽

2021 ◽

Vol 30 (3) ◽

pp. 253-263

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy ◽

Management of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19124 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19124-e19124

Author(s):

Yukio Hosomi ◽

Chiharu Tanai ◽

Kiyotaka Yoh ◽

Yasushi Goto ◽

Yasuo Ohashi ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Radiological Progression ◽

First Line Therapy ◽

Line Therapy ◽

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

Annals of Translational Medicine ◽

10.21037/atm.2016.12.64 ◽

2017 ◽

Vol 5 (1) ◽

pp. 11-11

Author(s):

Shinkyo Yoon ◽

Dae Ho Lee ◽

Sang-We Kim

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

British Journal of Cancer ◽

10.1038/sj.bjc.6603393 ◽

2006 ◽

Vol 95 (8) ◽

pp. 998-1004 ◽

Cited By ~ 216

Author(s):

H Asahina ◽

◽

K Yamazaki ◽

I Kinoshita ◽

N Sukoh ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

Value in Health ◽

10.1016/j.jval.2011.02.459 ◽

2011 ◽

Vol 14 (3) ◽

pp. A82 ◽

Cited By ~ 4

Author(s):

W. Chen ◽

P. Ellis ◽

L. Levin ◽

M. Krahn

Keyword(s):

Lung Cancer ◽

Receptor Gene ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth ◽

Selection Of

Pharmacoeconomic Aspects of Different Inhibitors of Tyrosine Kinase in First-Line Therapy of Patients with Advanced Non-Small Cell Lung Cancer with A Mutation in Epidermal Growth Factor Receptor (EGFR) Gene

Value in Health ◽

10.1016/j.jval.2016.09.2139 ◽

2016 ◽

Vol 19 (7) ◽

pp. A720

Author(s):

VV Ryazhenov ◽

SG Gorokhova ◽

V Gorokhov

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

First Line Therapy ◽

Line Therapy ◽

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy

PLoS Currents ◽

10.1371/currents.rrn1245 ◽

2011 ◽

Vol 3 ◽

pp. RRN1245 ◽

Cited By ~ 2

Author(s):

Naoko Ishibe ◽

Josh Carlson ◽

Scott David Ramsey ◽

Andrew Freedman ◽

Sheri Schully

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Oncotarget ◽

10.18632/oncotarget.24386 ◽

2018 ◽

Vol 9 (36) ◽

pp. 24237-24247 ◽

Cited By ~ 6

Author(s):

Chih-Yen Tu ◽

Chuan-Mu Chen ◽

Wei-Chih Liao ◽

Biing-Ru Wu ◽

Chih-Yu Chen ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

150P Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30424-6 ◽

2018 ◽

Vol 13 (4) ◽

pp. S90-S91

Author(s):

M. Gottfried ◽

S. Keren Rosenberg ◽

J. Dudnik ◽

M. Wollner ◽

J. Bar ◽

...

Keyword(s):

Egfr Mutation ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽